Click Here to
News, Updates,
& More
Stay Up
to Date

ESMO 2020

In patients with newly diagnosed high-grade serous ovarian cancer, dose-dense weekly paclitaxel was associated with longer progression-free survival and higher frequency of grade 3/4 adverse events, including hematologic toxicities, versus paclitaxel given every 3 weeks.
Page 3 of 3
Results 21 - 21 of 21